Document:

EX-10.1

 Exhibit 10.1 

EXHIBIT D 
 FORM OF
CONTINGENT VALUE RIGHTS AGREEMENT 
 THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [_____], 2020 (this
“Agreement”), is entered into by and between Melinta Therapeutics, Inc., a Delaware corporation (“Parent”), and [____]1, as Rights Agent (the “Rights
Agent”). 
 RECITALS 

WHEREAS, Parent, Toronto Transaction Corp., a Delaware corporation and a wholly-owned subsidiary of Parent (“Merger
Sub”), and Tetraphase Pharmaceuticals, Inc., a Delaware corporation (including in its capacity as the surviving corporation in the Merger, the “Company”), have entered into an Agreement and Plan of Merger dated as of
June 4, 2020 (as it may be amended or supplemented from time to time pursuant to the terms thereof, the “Merger Agreement”); 

WHEREAS, capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Merger Agreement; 

WHEREAS, pursuant to the Merger Agreement, Merger Sub has agreed to commence a tender offer (the “Offer”) to purchase
all of the outstanding shares of Company Common Stock in exchange for: (i) the Cash Consideration, and (ii) one contingent value right per Share, as hereinafter described (together with the Cash Consideration, the
“Consideration”); 
 WHEREAS, following completion of the Offer, at the Effective Time, Merger Sub will merge with
and into the Company (the “Merger”), with the Company continuing as the surviving corporation and as a wholly owned subsidiary of Parent; 

WHEREAS, pursuant to and on the terms set forth in the Merger Agreement, each Share shall be converted at the Effective Time into the
right to receive the Consideration, including the contingent value rights as hereinafter described; and 
 WHEREAS, the Rights Agent
is willing to act in connection with the issuance, transfer, exchange and payment of such contingent value rights as provided herein. 

NOW, THEREFORE, in consideration of the premises and mutual agreements herein, Parent and the Rights Agent hereby agree as follows:

 1. DEFINITIONS 

1.1    Definitions. As used in this Agreement, the following terms shall have the following meanings: 

 
  

	1 	 Note to Draft: Rights Agent to be determined in accordance with the Merger Agreement.

 “Acting Holders” means, at the time of determination, Holders of at least
40% of the outstanding CVRs as set forth on the CVR Register. 
 “Affiliate” means, with respect to any specified Person,
any other Person that, directly or indirectly, through one or more intermediaries, controls, is controlled by or is under common control with such specified Person; “control” means the ownership, directly or indirectly, of more than 50% of
the voting securities entitled to vote for the directors (or similar officials) of a Person or the possession, by contract or otherwise, of the authority to direct the management and policies of a Person. 

“Calendar Quarter” means each period of three consecutive months commencing on January 1, April 1, July 1 and
October 1 of each calendar year. 
 “Calendar Year” means the period of four consecutive Calendar Quarters beginning
on January 1 and ending on December 31 of each calendar year. 
 “Change of Control” means (i) a sale or
other disposition of all or substantially all of the assets of either Parent or the Company on a consolidated basis (other than to any direct or indirect wholly owned subsidiary of Parent), (ii) a merger or consolidation involving either Parent or
the Company in which Parent or the Company, respectively, is not the surviving entity, and (iii) any other transaction involving either Parent or the Company in which Parent or the Company, respectively, is the surviving entity but in which the
stockholders of Parent or the Company, respectively, immediately prior to such transaction own less than fifty percent (50%) of the surviving entity’s voting power immediately after the transaction, other than any bona fide equity
financing transaction solely related to the continued financing of the operations of Parent and its subsidiaries. 
 “Commercially
Reasonable Efforts” means, with respect to a task related to a product, the efforts required to carry out such task in a diligent and sustained manner without undue interruption, pause or delay, which level is at least commensurate with the
level of efforts that a pharmaceutical company of comparable size and resources as those of Parent and its controlled Affiliates would devote to a product of similar potential (including commercial potential), taking into account its proprietary
position and profitability (including pricing and reimbursement status, but excluding the obligation to pay the Milestone Amounts under this Agreement), anticipated or actual market conditions and economic return potential, the regulatory
environment, and other relevant technical, commercial, legal, scientific and/or medical factors. 
 “CVRs” means the rights
of Holders to receive contingent payments of cash pursuant to the Merger Agreement and this Agreement. 
 “CVR Register”
has the meaning set forth in Section 2.3(b). 
 “DTC” means The Depository Trust Company or any successor entity
thereto. 
 “Event of Default” has the meaning set forth in Section 6.1(a). 

“Holder” means a Person in whose name a CVR is registered in the CVR Register at the applicable time. 

  
 2 

 “Independent Accountant” has the meaning set forth in Section 4.5(a).

 “Licensee” means any non-Affiliate third party granted a license by Parent or
its Affiliates under the Company IP to make, have made, use, sell, offer for sale, or import XERAVA in the U.S., but shall exclude any (i) third party distributor of XERAVA that has no royalty or other payment obligations to any Parent or any
of its Affiliates that are calculated based on amounts invoiced or received by such third party for sales of XERAVA or (ii) a third party distributor of XERAVA that (x) does not take title to XERAVA, (y) does not invoice XERAVA sales
to third party customers and (z) is responsible only for inventory management and distribution with respect XERAVA on behalf of Parent or its Affiliates. 

“Milestone” means each of Milestone 1, Milestone 2 and Milestone 3. 

“Milestone 1” means the first achievement of annual Net Sales of at least $20,000,000 during the Calendar Year ending on
December 31, 2021. 
 “Milestone 2” means the first achievement of annual Net Sales of at least $35,000,000 during any
Calendar Year ending on or before December 31, 2024. 
 “Milestone 3” means the first achievement of annual Net Sales
of at least $55,000,000 during any calendar year ending on or before December 31, 2024. 
 “Milestone Amount” means
each of Milestone 1 Amount, Milestone 2 Amount and Milestone 3 Amount. 
 “Milestone 1 Amount” means, with respect to the
achievement of Milestone 1, an amount per CVR equal to the quotient of $2,500,000, divided by the aggregate number of CVRs issued pursuant to the Merger Agreement and this Agreement, without interest (it being understood and agreed that all
Milestones or a combination of any two Milestones can be earned in the same year, in which case all such applicable Milestone Amounts shall be payable). 

“Milestone 2 Amount” means, with respect to the achievement of Milestone 2, an amount per CVR equal to the quotient of
$4,500,000, divided by the aggregate number of CVRs issued pursuant to the Merger Agreement and this Agreement, without interest (it being understood and agreed that all Milestones or a combination of any two Milestones can be earned in the same
year, in which case all such applicable Milestone Amounts shall be payable). 
 “Milestone 3 Amount” means, with respect to
the achievement of Milestone 3, an amount per CVR equal to the quotient of $9,000,000, divided by the aggregate number of CVRs issued pursuant to the Merger Agreement and this Agreement, without interest (it being understood and agreed that all
Milestones or a combination of any two Milestones can be earned in the same year, in which case all such applicable Milestone Amounts shall be payable). 

“Milestone Cap” means $16,000,000. 

“Milestone Non-Achievement Certificate” has the meaning set forth in
Section 2.4(e). 
 “Milestone Notice” has the meaning set forth in Section 2.4(a)(i). 

  
 3 

 “Milestone Payment Date” has the meaning set forth in Section 2.4(a).

 “Net Sales” means the gross amount invoiced by Parent, any of its Affiliates (including the Surviving Corporation) or
any of its Licensees (each, a “Selling Party”) to a third party for sales or distribution of XERAVA in the U.S., less the following deductions as calculated in accordance with GAAP consistently applied: 

(i)    customary trade, cash and quantity discounts given to customers; 

(ii)    rebates, credits and allowances given by reason of rejections returns, damaged or defective product or recalls;

 (iii)    government-mandated rebates, credits and adjustments paid or deducted; 

(iv)    customary price adjustments, allowances, credits, chargeback payments, discounts, rebates, free of charge
concessions, fees and reimbursements granted or made to managed care organizations, group purchasing organizations or other buying groups, pharmacy benefit management companies, health maintenance organizations and any other providers of health
insurance coverage, health care organizations or other health care institutions (including hospitals), health care administrators, patient assistance or other similar programs, or to federal state/provincial, local and other governments, including
their agencies; 
 (v)    reasonable and customary freight, shipping, insurance and other transportation expenses, if
borne by the applicable Selling Party without reimbursement from any third party; 
 (vi)    amounts written off as
uncollectable debt; provided that the amount of any uncollectable debt deducted pursuant to this exception and actually collected in a subsequent Calendar Quarter shall be included in Net Sales for such subsequent Calendar Quarter; and 

(vii)    sales, value-added, excise taxes, tariffs and duties, and other taxes and government charges directly related to
the sale, delivery or use of XERAVA (but not including taxes assessed against the net income derived from such sale). 
 Furthermore, Net
Sales shall not include use of or sale at or below the direct manufacturing cost of XERAVA by Parent, its Affiliates (including the Surviving Corporation) and/or its sublicensees of XERAVA for non-clinical or
clinical studies, patient-assistance programs or charitable donations. 
 Resales or sales of XERAVA made in good faith between or among any
Selling Party shall not be included in the calculation of Net Sales but the subsequent resale or sale to a non-Affiliate third party (other than a Selling Party) shall be included in the computation of Net
Sales. 
 All Net Sales shall be computed in Dollars, and where any Net Sales are calculated in a currency other than Dollars, they shall be
translated into Dollars in accordance with GAAP. 

  
 4 

 “Officer’s Certificate” means a certificate signed by the chief
executive officer, president, chief financial officer, any vice president, the controller, the treasurer or the secretary, in each case of Parent, in his or her capacity as such an officer, and delivered to the Rights Agent. 

“Permitted Transfer” means a transfer of CVRs (a) upon death of a Holder by will or intestacy; (b) by instrument to
an inter vivos or testamentary trust in which the CVRs are to be passed to beneficiaries upon the death of the trustee; (c) pursuant to a court order; (d) by operation of law (including by consolidation or merger) or without
consideration in connection with the dissolution, liquidation or termination of any corporation, limited liability company, partnership or other entity; (e) in the case of CVRs held in book-entry or other similar nominee form, from a nominee to
a beneficial owner and, if applicable, through an intermediary, as allowable by DTC; or (f) as provided in Section 2.10. 

“Rights Agent” means the Rights Agent named in the first paragraph of this Agreement, until a successor Rights Agent becomes
such pursuant to the applicable provisions of this Agreement, and thereafter “Rights Agent” shall mean such successor Rights Agent. 

“Share” means each share of Company Common Stock outstanding immediately prior to the Effective Time, except any
(i) shares of Company Common Stock held by the Company or any wholly-owned Subsidiary of the Company as of immediately prior to the Effective Time (or held in the Company’s treasury), (ii) shares of Company Common Stock held by Parent,
Merger Sub or any other wholly-owned Subsidiary of Parent as of immediately prior to the Effective Time or (iii) Dissenting Company Shares. 

“U.S.” means the United States of America and its territories, districts and possessions. 

1.2    Rules of Construction. For purposes of this Agreement, the parties hereto agree that: (a) whenever the
context requires, the singular number shall include the plural, and vice versa; (b) the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender
shall include masculine and feminine genders; (c) the word “extent” in the phrase “to the extent” means the degree to which a subject or other thing extends, and does not simply mean “if”; (d) the words
“include” and “including,” and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words “without limitation;” (e) the meaning assigned to each capitalized
term defined and used in this Agreement is equally applicable to both the singular and the plural forms of such term, and words denoting any gender include all genders; (f) where a word or phrase is defined in this Agreement, each of its other
grammatical forms has a corresponding meaning unless the context otherwise requires; (g) a reference to any specific Legal Requirement or to any provision of any Legal Requirement includes any amendment to, and any modification, re-enactment or successor thereof, any legislative provision substituted therefor and all rules, regulations and statutory instruments issued thereunder or pursuant thereto; (h) references to any agreement or
Contract are to that agreement or Contract as amended, modified or supplemented; (i) they have been represented by legal counsel during the negotiation and execution and delivery of this Agreement and therefore waive the application of any
Legal Requirement, holding or rule of construction providing that ambiguities in an agreement or other document will be construed against the party drafting such agreement or 

  
 5 

 
document; and (j) the word “or” shall not be exclusive (i.e., “or” shall be deemed to mean “and/or”) unless the subjects of the conjunction are mutually
exclusive. The headings contained in this Agreement are for convenience of reference only, shall not be deemed to be a part of this Agreement and shall not be referred to in connection with the construction or interpretation of this Agreement. All
references to “Dollars” or “$” are to United States Dollars, unless expressly stated otherwise. 
 2. CONTINGENT VALUE RIGHTS

 2.1    CVRs. 

(a)    As provided in the Merger Agreement: 

(i)    effective as of the Acceptance Time, Merger Sub will accept for payment and pay the Consideration, including one
CVR, for each share of Company Common Stock validly tendered and not validly withdrawn pursuant to the Offer; and 

(ii)    effective as of the Effective Time, (A) each Share shall be converted into the right to receive the
Consideration, which includes one CVR, and (B) each Company Warrant that is assumed and converted pursuant to Section 5.2(c) of the Merger Agreement shall be treated in accordance with its terms. 

(b)    The initial Holders shall be determined pursuant to the terms of the Merger Agreement and this Agreement, and a
list of the initial Holders shall be furnished to the Rights Agent by or on behalf of Parent in accordance with Section 4.1 hereof. 

2.2    Non-transferable. The CVRs may not be sold, assigned, transferred,
pledged, encumbered or in any other manner transferred or disposed of, in whole or in part, other than through a Permitted Transfer, and, in the case of a Permitted Transfer, only in accordance with Section 2.3(c) hereof and in compliance with
applicable United States federal and state securities laws and the terms and conditions hereto. Any such sale, assignment, transfer, pledge, encumbrance or disposal of CVRs, in whole or in part, in violation of this Section 2.2, shall be null
and void and of no effect. 
 2.3    No Certificate; Registration; Registration of Transfer; Change of Address.

 (a)    The CVRs shall not be evidenced by a certificate or other instrument. 

(b)    The Rights Agent shall keep a register (the “CVR Register”) for the purpose of identifying the
Holders and registering CVRs and transfers of CVRs as herein provided. The CVR Register will initially show one position for Cede & Co. representing all of the CVRs that are issued to the holders of Shares held by DTC on behalf of the
street holders of the Shares. The Rights Agent will have no responsibility whatsoever directly to the street name holders or DTC participants with respect to transfers of CVRs. With respect to any payments to be made under Section 2.4 below,
the Rights Agent will accomplish such payment to any former street name holders of the Shares by sending such payments to DTC. The Rights Agent will have no responsibilities whatsoever with regard to the distribution of payments by DTC to such
street name holders. 

  
 6 

 (c)    Subject to the restrictions on transferability set forth in
Section 2.2, every request made to transfer a CVR must be in writing and accompanied by a written instrument of transfer in form reasonably satisfactory to the Rights Agent pursuant to its written guidelines, duly executed by the Holder
thereof, the Holder’s attorney duly authorized in writing, the Holder’s personal representative or the Holder’s survivor, as applicable, and setting forth in reasonable detail the circumstances relating to the transfer. Upon receipt
of such written notice, the Rights Agent shall, subject to its reasonable determination that the transfer instrument is in proper form and the transfer otherwise complies with the other terms and conditions of this Agreement (including the
provisions of Section 2.2), register the transfer of the CVRs in the CVR Register and notify the Parent of the same. Any registration, transfer or assignment of the CVRs shall be without charge to the Holder (other than payment of a sum to the
extent necessary to cover any stamp or other Tax or other governmental charge that is imposed in connection with any such registration, transfer or assignment). All duly transferred CVRs registered in the CVR Register shall be the valid obligations
of Parent and shall entitle the transferee to the same benefits and rights under this Agreement as those held immediately prior to the transfer by the transferor. No transfer of a CVR shall be valid unless and until registered in the CVR Register.

 (d)    A Holder may make a written request to the Rights Agent to change such Holder’s address of record in the
CVR Register. The written request must be duly executed by the Holder. Upon receipt of such written request, the Rights Agent is hereby authorized to, and shall promptly, record the change of address in the CVR Register. 

2.4    Payment Procedures. 

(a)    If any Milestone is achieved, then, in each case, on a date (a “Milestone Payment Date”) that is
within 60 days following the last day of such Calendar Quarter in which such Milestone is achieved: 
 (i)    Parent
will deliver to the Rights Agent (A) a notice (a “Milestone Notice”) indicating the achievement of such Milestone and that the Holders are entitled to receive the applicable Milestone Amount, and (B) for each CVR, cash in
the aggregate amount of the Milestone Amount. 
 (ii)    Subject to the terms of this Agreement, each CVR shall entitle
the Holder thereof to receive from the Rights Agent (on behalf of Parent), for each CVR, the Milestone Amount, in each case subject to any applicable withholding Tax. 

(b)    The Rights Agent shall promptly, and in any event within 10 Business Days of receipt of a Milestone Notice, as well
as any letter of instruction reasonably required by the Rights Agent, send each Holder at its registered address a copy of such Milestone Notice. At the time the Rights Agent sends a copy of such Milestone Notice to the Holders, the Rights Agent
shall also pay to each Holder, subject to any applicable withholding Tax, the applicable Milestone Amount (the amount of which each Holder is entitled to receive shall be based on the applicable Milestone Amount multiplied by the number of CVRs held
by such Holder as reflected in the CVR Register), in accordance with the corresponding letter of instruction (i) by check mailed to the address of such Holder reflected in the CVR Register as of 5:00 p.m. New York City time on the date of the
applicable Milestone Notice or (ii) with respect to any such 

  
 7 

 
Holder that is due an amount in excess of $100,000 in the aggregate who has provided the Rights Agent wiring instructions in writing as of the close of business on the date of the Milestone
Notice, by wire transfer of immediately available funds to the account specified on such instruction. 

(c)    Notwithstanding any other provisions of this Agreement, any portion of the amounts payable pursuant to
Section 2.4(b) that remains unclaimed as of the first anniversary of the applicable Milestone Payment Date (including by means of uncashed checks or invalid addresses on the CVR Register) shall be delivered to Parent or its designee and not
disbursed to the Holders, and, thereafter, such Holders shall be entitled to look to Parent (subject to abandoned property, escheat and other similar Laws) only as general creditors thereof with respect to such cash that may be payable. 

(d)    Neither Parent, the Rights Agent nor any of their Affiliates shall be liable to any Holder for any payments
delivered to a public official pursuant to any abandoned property, escheat law or other similar Legal Requirements. 

(e)    If a Milestone is not achieved during any one of the 2021, 2022, 2023 or 2024 Calendar Years, then on or before the
date that is 60 days after the expiration of each such applicable Calendar Year period, Parent shall deliver to the Rights Agent a certificate certifying that such Milestone has not occurred, accompanied by a statement setting forth, in reasonable
detail, a calculation of Net Sales for the applicable period (each, a “Milestone Non-Achievement Certificate”). The Rights Agent shall promptly, and in any event within 10 Business Days of receipt of a Milestone Non-Achievement Certificate, send each Holder at its registered address a copy of such Milestone Non-Achievement Certificate, including detail regarding the ability of a
Holder or Holders to dispute or contest such determination of non-achievement of a Milestone pursuant to this Agreement. If the Rights Agent does not receive from the Acting Holders a written objection to
(i) a Milestone Non-Achievement Certificate with respect to Milestone 1, if any, within 180 days of the delivery by the Rights Agent of such Milestone
Non-Achievement Certificate to the Holders in accordance with this Section 2.4(e), the Holders shall be deemed to have accepted such Milestone Non-Achievement
Certificate and Parent and its Affiliates shall have no further obligation with respect to Milestone 1 and the Milestone 1 Amount, and/or (ii) a Milestone Non-Achievement Certificate with respect to
Milestone 2 Milestone 3, and/or Milestone 4, if any, within 180 days of the delivery by the Rights Agent of such Milestone Non-Achievement Certificate with respect the 2024 Calendar Year to the Holders in
accordance with this Section 2.4(e), the Holders shall be deemed to have accepted such Milestone Non-Achievement Certificate and Parent and its Affiliates shall have no further obligation with respect to
each such Milestone and the applicable Milestone Amount. 
 (f)    Notwithstanding anything herein to the contrary, in
no event shall the aggregate payments to Holders under this Section 2 exceed the Milestone Cap. 

2.5    Withholding. Each of Parent, the Rights Agent, the Exchange Agent, the Surviving Corporation, their
respective Affiliates, and any other Person who has any obligation to deduct or withhold from any consideration payable pursuant to this Agreement shall be entitled to deduct and withhold from the amounts otherwise payable pursuant to this Agreement
such amounts as are required by any law to be deducted and withheld, as may be reasonably 

  
 8 

 
determined by such Person. To the extent that amounts are so withheld and remitted to the appropriate Governmental Body in accordance with applicable Legal Requirements, such withheld amounts
shall be treated for all purposes of this Agreement as having been paid to the Person in respect of which such deduction and withholding was made. 

2.6    Adjustment of CVRs. 

(a)    In case of any Change of Control, appropriate adjustment shall be made in the application of the provisions herein
set forth with respect to the rights and interests of Holders so that the provisions set forth herein shall thereafter be applicable, as nearly as possible, in relation to any cash thereafter deliverable upon payment of CVRs. 

(b)    Whenever an adjustment is made to the terms of the CVRs pursuant to this Section 2.6, Parent will deliver to
the Rights Agent a notice of such Change of Control within 3 Business Days of the closing of such Change of Control, setting forth in reasonable detail the terms of such Change of Control and any adjustments made pursuant to this Section 2.6.
The Rights Agent shall promptly, and in any event within 10 Business Days of receipt of such a notice, send each Holder a copy of such notice in accordance with Section 7.2. 

(c)    The Rights Agent has no duty to determine when an adjustment under this Section 2.6 should be made, how it
should be made or what it should be. The Rights Agent shall not be responsible for the Parent’s failure to comply with this Section 2.6. 

2.7    Notices to CVR Holders. Upon any adjustment pursuant to Section 2.6, Parent shall give prompt written
notice of such adjustment to the Rights Agent and shall cause the Rights Agent, on behalf of and at the expense of Parent, within 10 days after notification is received by the Rights Agent of such adjustment, to mail by first class mail, postage
prepaid, to each Holder a notice of such adjustment(s) and shall deliver to the Rights Agent a certificate of the Chief Financial Officer of Parent, setting forth in reasonable detail (i) the terms of such adjustment(s), (ii) a brief statement
of the facts requiring such adjustment(s) and (iii) the computation by which such adjustment(s) was made. Where appropriate, such notice by Parent may be given in advance and included as a part of the notice to the Holders required under the
other provisions of this Section 2.7. 
 2.8    Holding of Funds. All funds received by the Rights Agent
under this Agreement that are to be distributed or applied by the Rights Agent in the performance of services hereunder (the “Funds”) shall be held by the Rights Agent as agent for Parent and deposited in one or more bank accounts
to be maintained by the Rights Agent in its name as agent for Parent. Until paid pursuant to the terms of this Agreement, the Rights Agent will hold the Funds through such accounts in: deposit accounts of commercial banks with Tier 1 capital
exceeding $1 billion or with an average rating above investment grade by S&P (LT Local Issuer Credit Rating), Moody’s (Long Term Rating) and Fitch Ratings, Inc. (LT Issuer Default Rating) (each as reported by Bloomberg Finance L.P.).
The Rights Agent shall have no responsibility or liability for any diminution of the Funds that may result from any deposit made by the Rights Agent in accordance with this paragraph, including any losses resulting from a default by any bank,
financial institution or other third party; provided that in the event the Funds are diminished below the level required for the Rights Agent to make cash payments as required under this 

  
 9 

 
Agreement, including any such diminishment as a result of investment losses, Parent shall promptly pay additional cash to the Rights Agent in an amount equal to the deficiency in the amount
required to make such payments. The Rights Agent may from time to time receive interest, dividends or other earnings in connection with such deposits. The Rights Agent shall not be obligated to pay such interest, dividends or earnings to the Parent,
any Holder or any other Person, unless there is a diminution of the Funds due to a deposit or investment made by the Rights Agent, in which case, the Rights Agent agrees that such interest, dividends or earnings shall accrue to the benefit of Parent
to the extent of such diminution of the Funds. 
 2.9    No Voting, Dividends or Interest; No Equity or Ownership
Interest. 
 (a)    Nothing contained in this Agreement shall be construed as conferring upon any Holder, by virtue
of being a Holder of a CVR, the right to receive dividends or the right to vote or to consent or to receive notice as stockholders in respect of the meetings of stockholders or the election of directors of Parent or any constituent company to the
Merger or any of their respective Subsidiaries or Affiliates or any other matter, or any other rights of any kind or nature whatsoever as a stockholder of Parent or in any constituent company to the Merger or any of their respective Subsidiaries or
Affiliates, either at law or in equity. 
 (b)    The CVRs shall not represent any equity or ownership interest in
Parent or in any constituent company to the Merger or any of their respective Subsidiaries or Affiliates. The rights of a Holder in respect of the CVRs are limited to those expressed in this Agreement and the Merger Agreement. 

2.10    Ability to Abandon CVR. A Holder may at any time, at such Holder’s option, abandon all of such
Holder’s remaining rights in a CVR by transferring such CVR to Parent or any of its Affiliates without consideration therefor. Nothing in this Agreement shall prohibit Parent or any of its Affiliates from offering to acquire or acquiring any
CVRs for consideration from the Holders, in private transactions or otherwise, in its sole discretion. Any CVRs acquired by Parent or any of its Affiliates shall be automatically deemed extinguished and no longer outstanding for purposes of the
definition of Acting Holders and Section 5 and Section 6. 
 3. THE RIGHTS AGENT 

3.1    Certain Duties and Responsibilities. Parent hereby appoints the Rights Agent to act as rights agent for
Parent in accordance with the express terms and conditions set forth in this Agreement (and no implied terms and conditions), and the Rights Agent hereby accepts such appointment. The Rights Agent shall not have any liability for any actions taken,
suffered or omitted to be taken in connection with this Agreement, except to the extent of its gross negligence, bad faith or willful or intentional misconduct. 

3.2    Certain Rights of the Rights Agent. The Rights Agent undertakes to perform such duties and only such duties
as are specifically set forth in this Agreement, and no implied covenants or obligations shall be read into this Agreement against the Rights Agent. In addition: 

(a)    the Rights Agent may rely and shall be protected and held harmless by Parent in acting or refraining from acting
upon any resolution, certificate, statement, instrument, 

  
 10 

 
opinion, report, notice, request, direction, consent, order or other paper or document believed by it in good faith to be genuine and to have been signed or presented by the proper party or
parties; 
 (b)    whenever the Rights Agent shall deem it desirable that a matter be proved or established prior to
taking, suffering or omitting any action hereunder, the Rights Agent may rely upon an Officer’s Certificate, which certificate shall be full authorization and protection to the Rights Agent, and the Rights Agent shall, in the absence of gross
negligence, bad faith or willful or intentional misconduct on its part, incur no liability and be held harmless by Parent for or in respect of any action taken, suffered or omitted to be taken by it under the provisions of this Agreement in reliance
upon such certificate; 
 (c)    the Rights Agent may engage and consult with counsel of its selection and the written
advice of such counsel or any opinion of counsel shall be full and complete authorization and protection and shall be held harmless by Parent in respect of any action taken, suffered or omitted by it hereunder in good faith and in reliance thereon;

 (d)    the permissive rights of the Rights Agent to do things enumerated in this Agreement shall not be construed as
a duty; 
 (e)    the Rights Agent shall not be required to give any note or surety in respect of the execution of such
powers or otherwise in respect of the premises; 
 (f)    the Rights Agent shall not be liable for or by reason of, and
shall be held harmless by Parent with respect to any of the statements of fact or recitals contained in this Agreement or be required to verify the same, but all such statements and recitals are and shall be deemed to have been made by Parent only;

 (g)    the Rights Agent shall have no liability and shall be held harmless by Parent in respect of the validity of
this Agreement or the execution and delivery hereof (except the due execution and delivery hereof by the Rights Agent and the enforceability of this Agreement against the Rights Agent assuming the due execution and delivery hereof by Parent); nor
shall it be responsible for any breach by Parent of any covenant or condition contained in this Agreement; 

(h)    Parent agrees to indemnify the Rights Agent for, and hold the Rights Agent harmless against, any loss, liability,
damage, judgement, fine, penalty, claim, demands, suits or expense arising out of or in connection with Rights Agent’s duties under this Agreement, including the reasonable
out-of-pocket costs and expenses of counsel in defending Rights Agent against any loss, liability, damage, judgement, fine, penalty, claim, demands, suits or expense,
unless such loss has been determined by a court of competent jurisdiction to be a result of Rights Agent’s gross negligence, bad faith or willful or intentional misconduct; 

(i)    Anything to the contrary notwithstanding, in the absence of fraud or willful or intentional misconduct on the part
of the Rights Agent, (i) the Rights Agent shall not be liable for any special, punitive, indirect, consequential or incidental loss or damage of any kind whatsoever (including but not limited to lost profits) arising out of any act or failure
to act hereunder, even if the Rights Agent has been advised of the likelihood of such loss or damage or 

  
 11 

 
has foreseen the possibility or likelihood of such damages and (ii) the aggregate liability of the Rights Agent arising in connection with this Agreement, whether in contract, or in tort, or
otherwise, is limited to, and shall not exceed, the amounts paid or payable hereunder by Parent to the Rights Agent as fees and charges; 

(j)    Parent agrees (i) to pay the fees and expenses of the Rights Agent in connection with this Agreement agreed
upon in writing by the Rights Agent and Parent prior to the date hereof, and (ii) to reimburse the Rights Agent for all taxes and governmental charges, reasonable
out-of-pocket expenses and other charges of any kind and nature incurred by the Rights Agent in the execution of this Agreement (other than Taxes imposed on or measured
by the Rights Agent’s net income and franchise or similar Taxes imposed on it (in lieu of net income Taxes)); and 

(k)    No provision of this Agreement shall require the Rights Agent to expend or risk its own funds or otherwise incur
any financial liability in the performance of any of its duties hereunder or in the exercise of its rights if there shall be reasonable grounds for believing that repayment of such funds or adequate indemnification against such risk or liability is
not reasonably assured to it. 
 3.3    Resignation and Removal; Appointment of Successor. 

(a)    The Rights Agent may resign at any time by giving written notice thereof to Parent specifying a date when such
resignation shall take effect, which notice shall be sent at least 60 days prior to the date so specified but in no event shall such resignation become effective until a successor Rights Agent has been appointed and accepted such appointment in
accordance with Section 3.4. Parent has the right to remove the Rights Agent at any time by specifying a date when such removal shall take effect but no such removal shall become effective until a successor Rights Agent has been appointed and
accepted such appointment in accordance with Section 3.4. Notice of such removal shall be given by Parent to the Rights Agent, which notice shall be sent at least 60 days prior to the date so specified. 

(b)    If the Rights Agent provides notice of its intent to resign, is removed or becomes incapable of acting, Parent
shall, as soon as is reasonably practicable, appoint a qualified successor Rights Agent who shall be a stock transfer agent of national reputation or the corporate trust department of a commercial bank. Notwithstanding the foregoing, if Parent shall
fail to make such appointment within a period of sixty (60) days after giving notice of such removal or after it has been notified in writing of such resignation or incapacity by the resigning or incapacitated Rights Agent, then the incumbent
Rights Agent may apply to any court of competent jurisdiction for the appointment of a new Rights Agent. The successor Rights Agent so appointed shall, forthwith upon its acceptance of such appointment in accordance with Section 3.4, become the
successor Rights Agent. 
 (c)    Parent shall give notice of each resignation and each removal of a Rights Agent and
each appointment of a successor Rights Agent through the facilities of DTC in accordance with DTC’s procedures and/or by mailing written notice of such event by first-class mail to the Holders as their names and addresses appear in the CVR
Register. Each notice shall include the name and address of the successor Rights Agent. If Parent fails to send such notice 

  
 12 

 
within 10 Business Days after acceptance of appointment by a successor Rights Agent, the successor Rights Agent shall cause the notice to be transmitted at the expense of Parent. Failure to give
any notice provided for in this Section 3.3, however, shall not affect the legality or validity of the resignation or removal of the Rights Agent or the appointment of the successor Rights Agent, as the case may be. 

(d)    Notwithstanding anything else in this Section 3.3, unless consented to in writing by the Acting Holders,
Parent shall not appoint as a successor Rights Agent any Person that is not a stock transfer agent of national reputation or the corporate trust department of an international commercial bank. 

(e)    Acceptance of Appointment by Successor. Every successor Rights Agent appointed hereunder shall, at or prior
to such appointment, execute, acknowledge and deliver to Parent and to the retiring Rights Agent an instrument accepting such appointment and a counterpart of this Agreement, and thereupon such successor Rights Agent, without any further act, deed
or conveyance, shall become vested with all the rights, powers, trusts and duties of the retiring Rights Agent. On request of Parent or the successor Rights Agent, the retiring Rights Agent shall execute and deliver an instrument transferring to the
successor Rights Agent all the rights, powers, trusts and duties of the retiring Rights Agent. 
 4. COVENANTS 

4.1    List of Holders. Parent shall furnish or cause to be furnished to the Rights Agent the names and addresses of
the Holders within 10 days of the Effective Time. 
 4.2    Books and Records. Parent shall, and shall cause its
subsidiaries to, keep true, complete and accurate records in sufficient detail to enable the Holders and their consultants or professional advisors to determine the amounts payable hereunder. 

4.3    Payment of Milestone Amounts. Parent shall duly and promptly deposit with the Rights Agent for payment to
the Holders the Milestone Amounts in the manner provided for in Section 2.4 and in accordance with the terms of this Agreement. 

4.4    Further Assurances. Parent agrees that it will perform, execute, acknowledge and deliver or cause to be
performed, executed, acknowledged and delivered, all such further and other acts, instruments and assurances as may reasonably be required by the Rights Agent for the carrying out or performing by the Rights Agent of the provisions of this
Agreement. 
 4.5    Audit Rights. 

(a)    Until December 31, 2025, upon reasonable advance written notice from the Acting Holders, Parent shall permit
an independent certified public accounting firm of nationally recognized standing selected by such Acting Holders and reasonably acceptable to Parent (the “Independent Accountant”) to have access at reasonable times during normal
business hours to the books and records of Parent and its Affiliates as may be reasonably necessary to evaluate and verify Parent’s calculation of Net Sales hereunder; provided that (x) such Acting Holders (and the Independent Accountant)
enter into customary confidentiality 

  
 13 

 
agreements reasonably satisfactory to Parent with respect to the confidential information of Parent or its Affiliates to be furnished pursuant to this Section 4.5 and (y) such access
does not unreasonably interfere with the conduct of the business of Parent or any of its Affiliates. The fees charged by such accounting firm shall be borne by Parent. The Independent Accountant shall provide Parent with a copy of all disclosures
made to the Acting Holders. The decision of such accounting firm shall be final, conclusive and binding on Parent and the Holders, shall be nonappealable and shall not be subject to further review, absent manifest error. Parent shall not enter into
any transaction constituting a Change of Control unless such agreement contains provisions that would permit such accounting firm with such access to the records of the other party in such Change of Control if and to the extent as are reasonably
necessary to ensure compliance with this Section 4.5. The audit rights set forth in this Section 4.5(a) may not be exercised by the Acting Holders more than once in any given twelve (12) month period. 

(b)    If, in accordance with the procedures set forth in Section 4.5(a), the Independent Accountant concludes that
any Milestone Amount should have been paid but was not paid when due, Parent shall promptly, and in any event within thirty (30) days of the date the Independent Accountant delivers to Parent the Independent Accountant’s written report,
pay each Holder such Milestone Amount (to the extent not paid on a subsequent date), plus interest at the thirty (30) day U.S. dollar “prime rate” effective for the date such payment was due, as reported by Bloomberg, from when such
Milestone Amount should have been paid, as applicable, to the date of actual payment, pursuant to Section 2.4(a)(i) and Section 2.4(b), as applicable. 

4.6    Commercially Reasonable Efforts. Commencing upon the Closing and continuing until the earlier of
December 31, 2024 or the achievement of all Milestones, Parent shall, and shall cause its controlled Affiliates and Licensees to, use Commercially Reasonable Efforts to achieve the Milestones. Without limiting the foregoing, neither Parent nor
any of its controlled Affiliates shall act in bad faith for the purpose of avoiding achievement of any Milestone or the payment of any Milestone Amount. 

5. AMENDMENTS 

5.1    Amendments without Consent of Holders. 

(a)    Without the consent of any Holders, Parent, at any time and from time to time, may enter into one or more
amendments hereto, for any of the following purposes: 
 (i)    to evidence the succession of another person to Parent
and the assumption by any such successor of the covenants of Parent herein; provided that such succession and assumption is in accordance with the terms of this Agreement; 

(ii)    to evidence the succession of another Person as a successor Rights Agent and the assumption by any such successor
of the covenants and obligations of the Rights Agent herein; provided that such succession and assumption is in accordance with the terms of this Agreement; 

  
 14 

 (iii)    to add to the covenants of Parent such further covenants,
restrictions, conditions or provisions as Parent shall consider to be for the protection of the Holders; provided that, in each case, such provisions do not adversely affect the interests of the Holders; 

(iv)    to cure any ambiguity, to correct or supplement any provision herein that may be defective or inconsistent with
any other provision herein or in the Merger Agreement, or to make any other provisions with respect to matters or questions arising under this Agreement; provided that, in each case, such provisions do not adversely affect the interests of the
Holders; 
 (v)    as may be necessary or appropriate to ensure that the CVRs are not subject to registration under the
Securities Act, the Exchange Act or any applicable state securities or “blue sky” laws; provided that, such provisions shall not adversely affect the interests of the Holders; 

(vi)    to evidence the assignment of this Agreement by Parent as provided in Section 7.3; or 

(vii)    as may be necessary or appropriate to ensure that the Company complies with applicable law. 

In addition to the foregoing, upon the request of Parent, the Rights Agent hereby agrees to enter into one or more amendments hereto to evidence the
succession of another person as a successor Rights Agent in accordance with the terms of this Agreement and the assumption by any successor of the covenants and obligations of such Rights Agent herein, without modification of such covenants or
obligations other than as permitted by this Section 5.1. 
 (b)    Without the consent of any Holders, Parent and
the Rights Agent, at any time and from time to time, may enter into one or more amendments hereto to reduce the number of CVRs, in the event any Holder agrees to renounce such Holder’s rights under this Agreement in accordance with
Section 7.4 or to transfer CVRs to Parent pursuant to Section 2.10. 
 (c)    Promptly after the execution by
Parent and the Rights Agent of any amendment pursuant to the provisions of this Section 5.1, Parent shall mail (or cause the Rights Agent to mail) a notice thereof through the facilities of DTC in accordance with DTC’s procedures and/or by
first class mail to the Holders at their addresses as they appear on the CVR Register, setting forth such amendment. 

5.2    Amendments with Consent of Holders. 

(a)    Subject to Section 5.1 (which amendments pursuant to Section 5.1 may be made without the consent of any
Holder), with the written consent of the Holders of not less than a majority of the outstanding CVRs as set forth in the CVR Register, whether evidenced in writing or taken at a meeting of the Holders, Parent and the Rights Agent may enter into one
or more amendments hereto for the purpose of adding, eliminating or changing any provisions of this Agreement, even if such addition, elimination or change is materially adverse to the interest of the Holders. 

  
 15 

 (b)    Promptly after the execution by Parent and the Rights Agent of
any amendment pursuant to the provisions of this Section 5.2, Parent shall mail (or cause the Rights Agent to mail) a notice thereof through the facilities of DTC in accordance with DTC’s procedures and/or by first class mail to the
Holders at their addresses as they appear on the CVR Register, setting forth such amendment. 
 5.3    Execution of
Amendments. Prior to executing any amendment permitted by this Section 5, the Rights Agent shall be entitled to receive, and shall be fully protected in relying upon, an opinion of counsel selected by Parent and reasonably acceptable to
Rights Agent stating that the execution of such amendment is authorized or permitted by this Agreement. 

5.4    Effect of Amendments. Upon the execution of any amendment under this Section 5, this Agreement shall be
modified in accordance therewith, such amendment shall form a part of this Agreement for all purposes and every Holder shall be bound thereby. 
 6.
REMEDIES OF THE HOLDERS 
 6.1    Event of Default. 

(a)    “Event of Default” with respect to the CVRs, means each one of the following events which shall
have occurred and be continuing (whatever the reason for such Event of Default and whether it shall be voluntary or involuntary or be effected by operation of Legal Requirements, pursuant to any judgment, decree or order of any court or any order,
rule or regulation of any Governmental Body or otherwise): (i) default in the payment by Parent pursuant to the terms of this Agreement of all or any part of a Milestone Amount after a period of ten (10) Business Days after the Milestone Amount
shall become due and payable and (ii) material default in the performance, or breach in any material respect, of any other covenant or warranty of Parent hereunder, and continuance of such default or breach for a period of sixty (60) days
after a written notice specifying such default or breach and requiring it to be remedied is given, which written notice states that it is a “Notice of Default” hereunder and is sent by registered or certified mail to Parent and the Rights
Agent by the Acting Holders. 
 (b)    If an Event of Default described above occurs and is continuing (and has not been
cured or waived), then, and in each and every such case, the Acting Holders by notice in writing to Parent and the Rights Agent, may, in their discretion, commence a suit to protect the rights of the Holders, including to obtain payment for any
amounts then due and payable. 
 6.2    Suits by Holders. Except for the rights of the Rights Agent set forth
herein, the Acting Holders will have the sole right, on behalf of all Holders, by virtue of or under any provision of this Agreement, to institute any action or proceeding with respect to this Agreement, and no individual Holder or other group of
Holders will be entitled to exercise such rights. Notwithstanding the foregoing, (a) the right of any Holder of any CVR to receive payment of the amounts that a Milestone Notice indicates are payable in respect of such CVR on or after the
applicable due date, or to institute any action or proceeding for the enforcement of any such 

  
 16 

 
payment on or after such due date, shall not be impaired or affected without the consent of such Holder and (b) in the event of an insolvency proceeding of the Parent, individual Holders
shall be entitled to assert claims in such insolvency proceeding and take related actions in pursuit of such claims with respect to any payment that may be claimed by or on behalf of the Parent or by any creditor of the Parent. 

7. OTHER PROVISIONS OF GENERAL APPLICATION 

7.1    Notices to the Rights Agent and Parent. Any notice or other communication required or permitted to be
delivered to Parent or the Rights Agent under this Agreement shall be in writing and shall be deemed properly delivered, given and received (a) upon receipt when delivered by hand, (b) two Business Days after being sent by registered mail
or by courier or express delivery service, (c) if sent by email transmission prior to 6:00 p.m. recipient’s local time, upon transmission when receipt is confirmed or (d) if sent by email transmission after 6:00 p.m. recipient’s
local time and receipt is confirmed, the Business Day following the date of transmission; provided that in each case the notice or other communication is sent to the physical address or email address, as applicable, set forth beneath the name
of such party below (or to such other physical address or email address as such party shall have specified in a written notice given to the other party): 

If to the Rights Agent, to it at: 

[    ] 

[Address] 
 Attention:
[    ] 
 Facsimile: [    ] 

Email: [    ] 

If to Parent, to it at: 
 Melinta
Therapeutics, Inc. 
 44 Whippany Rd, Suite 280, 

Morristown, New Jersey 07960 

Attention: [_____] 
 E-mail: [_____] 
 with a copy to: 

[__________] 
 The Rights Agent
or Parent may specify a different address, facsimile number or email address by giving notice in accordance with this Section 7.1. 

7.2    Notice to Holders. Where this Agreement provides for notice to Holders, such notice shall be sufficiently
given (unless otherwise herein expressly provided) if in writing and transmitted through the facilities of DTC in accordance with DTC’s procedures or mailed, first-class postage prepaid, to each Holder affected by such event, at the
Holder’s address as it appears 

  
 17 

 
in the CVR Register, not later than the latest date, and not earlier than the earliest date, if any, prescribed for the giving of such notice. In any case where notice to Holders is given by
mail, neither the failure to mail such notice, nor any defect in any notice so mailed, to any particular Holder shall affect the sufficiency of such notice with respect to other Holders. 

7.3    Successors and Assigns. Parent may assign, in its sole discretion and without the consent of any other
Person, any or all of its rights, interests and obligations hereunder to one or more direct or indirect wholly owned subsidiaries of Parent for so long as they remain wholly owned subsidiaries of Parent and any such subsidiary may assign any or all
of its rights, interests and obligations hereunder to one or more other direct or indirect wholly owned subsidiaries of Parent for so long as they remain wholly owned subsidiaries of Parent; provided that each such assignee agrees to assume
and be bound by all of the terms and conditions of this Agreement; provided, further, that Parent shall remain liable for the performance by each such assignee of all covenants, agreements and obligations of Parent hereunder. This
Agreement will be binding upon, inure to the benefit of and be enforceable by Parent’s successors and each assignee. Each of Parent’s successors and each assignee shall, by a supplemental contingent consideration payment agreement or other
acknowledgement executed and delivered to the Rights Agent, expressly agree to assume and be bound by all of the terms and conditions of this Agreement. This Agreement shall not restrict Parent’s or any successor’s ability to merge or
consolidate or enter into or consummate any Change of Control; provided, that in the event of a Change of Control, Parent or the Company, as applicable, shall cause the acquirer to assume Parent’s obligations, duties and covenants under
this Agreement. Except as otherwise permitted herein, Parent may not assign this Agreement without the prior written consent of the Acting Holders. Any attempted assignment of this Agreement or any such rights in violation of this Section 7.3
shall be void and of no effect. 
 7.4    No Third Party Beneficiaries. Nothing in this Agreement, express or
implied, shall give to any Person (other than the Rights Agent and its permitted successors and assigns, Parent, Parent’s permitted successors and assignees, and the Holders and the Holders’ successors and assigns pursuant to Permitted
Transfers, each of whom is intended to be, and is, a third party beneficiary hereunder) any benefit or any legal or equitable right, remedy or claim under this Agreement or under any covenant or provision herein contained, all such covenants and
provisions being for the sole benefit of the Rights Agent and its permitted successors and assigns, Parent, Parent’s permitted successors and assignees, and the Holders and the Holders’ successors and assigns pursuant to Permitted
Transfers. The rights hereunder of Holders and their successors and assigns pursuant to Permitted Transfers are limited to those expressly provided in this Agreement. Notwithstanding anything to the contrary contained herein, any Holder or
Holder’s successor or assign pursuant to a Permitted Transfer may at any time agree to renounce, in whole or in part, whether or not for consideration, its rights under this Agreement by written notice to the Rights Agent and Parent, which
notice, if given, shall be irrevocable, and Parent may, in its sole discretion, at any time offer consideration to Holders in exchange for their agreement to irrevocably renounce their rights, in whole or in part, hereunder. 

7.5    Governing Law; Jurisdiction. This Agreement, the CVRs and all actions arising under or in connection
herewith and therewith (whether sounding in contract, tort or otherwise) shall be governed by and construed in accordance with the laws of the State of Delaware, without giving effect to any laws, rules or provisions that would cause the application
of the laws 

  
 18 

 
of any jurisdiction other than the State of Delaware. In any action between any of the parties arising out of or relating to this Agreement or the CVRs: (a) each of the parties irrevocably
and unconditionally consents and submits to the exclusive jurisdiction and venue of the Chancery Court of the State of Delaware; and (b) each of the parties irrevocably waives the right to trial by jury. All rights and remedies existing under
this Agreement are cumulative to, and not exclusive of, any rights or remedies otherwise available. 

7.6    Severability. In the event that any provision of this Agreement, or the application thereof, becomes or is
declared by a court of competent jurisdiction to be illegal, void or unenforceable, the remainder of this Agreement shall continue in full force and effect and the application of such provision to other Persons or circumstances shall be interpreted
so as reasonably to effect the intent of the parties. The parties further agree to replace such void or unenforceable provision of this Agreement with a valid and enforceable provision that will achieve, to the extent possible, the economic,
business and other purposes of such void or unenforceable provision. 
 7.7    Termination. This Agreement shall
be terminated and of no force or effect, the parties hereto shall have no liability hereunder (other than with respect to monies due and owing by Parent to Rights Agent), and no payments shall be required to be made, upon the earlier to occur of
(a) the payment in full of the Milestone 1 Amount, the Milestone 2 Amount and the Milestone 3 Amount, by the mailing by the Rights Agent to the address of each Holder as reflected in the CVR Register the full amount of each Milestone Amount as
required to be paid under the terms of this Agreement, (b) December 31, 2024, if Milestone 2 and/or Milestone 3 has not been achieved on or prior to such date, and (c) the termination of the Merger Agreement in accordance with its
terms. Notwithstanding the foregoing, no such termination shall affect any rights or obligations accrued prior to the effective date of such termination or Sections 2.4(c), 2.4(d), 2.4(e), 2.4(f), 3.2, 4.5, 7.4, 7.5, 7.6, 7.8, 7.9, 7.10 or this
Section 7.7, which shall survive the termination of this Agreement, or the resignation, replacement or removal of the Rights Agent. 

7.8    Entire Agreement; Counterparts. As it relates to the Rights Agent, this Agreement constitutes the entire
agreement of the parties hereto and supersedes all contemporaneous and prior agreements and understandings, both written and oral, among or between any of the parties hereto, with respect to the subject matter hereof. As between the Parent and the
Company this Agreement and the Merger Agreement constitute the entire agreement and supersede all contemporaneous and prior agreements and understandings, both written and oral, among or between any of the parties, with respect to the subject matter
hereof. If and to the extent that any provision of this Agreement is inconsistent or conflicts with the Merger Agreement, this Agreement shall govern and be controlling. This Agreement may be executed in counterparts, each of which shall be deemed
an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by PDF shall be sufficient to bind the parties hereto to the terms and conditions of this Agreement.

 7.9    No Fiduciary Obligations. Each of Parent and the Rights Agent acknowledges and agrees that the other
party, its Affiliates and their respective officers, directors and controlling Persons do not owe any fiduciary duties to the first party or any of its respective 

  
 19 

 
Affiliates, officers, directors or controlling Persons. The only obligations of the Parent and the Rights Agent to each other and their Affiliates and their respective officers, directors and
controlling Persons arising out of this Agreement are the contractual obligations expressly set forth in this Agreement. 

7.10    Confidentiality. The Rights Agent and the Parent agree that all books, records, information and data
pertaining to the business of the other party, including inter alia, personal, non-public Holder information, which are exchanged or received pursuant to the negotiation or the carrying out of this Agreement
including the fees for services set forth in the attached schedule shall remain confidential, and shall not be voluntarily disclosed to any other person, except as may be required by a valid order of an arbitration panel, court or governmental body
of competent jurisdiction or is otherwise required by law or regulation, including SEC or Nasdaq rules and regulations, or pursuant to subpoenas from state or federal government authorities (e.g., in divorce and criminal actions). 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 20 

 IN WITNESS WHEREOF, each of the parties has caused this Agreement to be executed on its
behalf by its duly authorized officers as of the day and year first above written. 
  

			
	MELINTA THERAPEUTICS, INC.

 
			
		
	By:	 	  

	Name:	 	
	Title:	 	

 
			
	
	[RIGHTS AGENT]

 
			
		
	By:	 	  

	Name:	 	  

	Title:	 	  

 [Signature Page to Contingent Value Rights Agreement]EX-10.2

 Exhibit 10.2 

FORM OF SUPPORT AGREEMENT 

This SUPPORT AGREEMENT (this “Agreement”), dated as of June 4, 2020, is entered into by and among Melinta Therapeutics,
Inc., a Delaware corporation (“Parent”), Toronto Transaction Corp., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”), and each of the stockholders of Tetraphase Pharmaceuticals, Inc. set
forth on Schedule A hereto (each, a “Stockholder”). Capitalized terms used but not otherwise defined in this Agreement shall have the respective meanings ascribed to such terms in the Merger Agreement (as defined below). 

WHEREAS, as of the date hereof, each Stockholder is the record and beneficial owner (as defined in Rule
13d-3 under the Exchange Act) of the number of shares of Company Common Stock set forth opposite such Stockholder’s name on Schedule A (all such shares, together with any Shares acquired by the
Stockholder after the date hereof (including any Shares acquired by means of purchase, stock split, divided, distribution, upon the exercise of any option or warrant or otherwise) the “Subject Shares”); 

WHEREAS, as of the date hereof, each Stockholder is the record and beneficial owner (as defined in Rule
13d-3 under the Exchange Act) of the Company Warrants to purchase Company Common Stock set forth opposite such Stockholder’s name on Schedule A (all such Company Warrants, the “Subject
Warrants”, and together with the Subject Shares, the “Subject Securities”); 
 WHEREAS, concurrently with the
execution hereof, Parent, Purchaser and Tetraphase Pharmaceuticals, Inc., a Delaware corporation (the “Company”), are entering into an Agreement and Plan of Merger, dated as of the date hereof (as it may be amended from time to
time, the “Merger Agreement”), which provides, among other things, that (i) Purchaser shall commence a tender offer (the “Offer”) to purchase all of the outstanding shares of Company Common Stock and
(ii) following the completion of the Offer, Purchaser shall be merged with and into the Company, with the Company surviving the Merger and becoming a wholly-owned subsidiary of Parent, in each case upon the terms and subject to the conditions
set forth in the Merger Agreement; and 
 WHEREAS, as a condition to their willingness to enter into the Merger Agreement, and as an
inducement and in consideration for Parent and Purchaser to enter into the Merger Agreement, each Stockholder, severally and not jointly, and on such Stockholder’s own account with respect to the Subject Shares, has agreed to enter into this
Agreement. 
 NOW, THEREFORE, in consideration of the foregoing and the respective representations, warranties, covenants and agreements set
forth below and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, do hereby agree as follows: 

 ARTICLE I 

AGREEMENT TO TENDER AND VOTE 

1.1    Agreement to Tender. Subject to the terms of this Agreement, each Stockholder hereby agrees to validly and
irrevocably tender or cause to be validly and irrevocably tendered in the Offer all of such Stockholder’s Subject Shares pursuant to and in accordance with the terms of the Offer, free and clear of all Encumbrances except for Permitted
Encumbrances (as defined below). Without limiting the generality of the foregoing, as promptly as practicable after, but in no event later than ten Business Days after, the commencement (within the meaning of Rule
14d-2 under the Exchange Act) of the Offer (or in the case of any shares of Company Common Stock acquired by such Stockholder subsequent to such tenth Business Day, or in each case if such Stockholder has not
received the Offer Documents by such time, as promptly as practicable after the acquisition of such shares or receipt of the Offer Documents, as the case may be), each Stockholder shall (a) deliver or cause to be delivered pursuant to the terms
of the Offer (i) a letter of transmittal with respect to all of such Stockholder’s Subject Shares complying with the terms of the Offer, (ii) a certificate representing all such Subject Shares that are certificated or, in the case of
a Book Entry Share, written instructions to such Stockholder’s broker, dealer or other nominee that such Subject Shares be tendered, including a reference to this Agreement, and requesting delivery of an “agent’s message” (or
such other evidence, if any, of transfer as the Exchange Agent may reasonably request) with respect to such Subject Shares, and (iii) all other documents or instruments that Parent or Purchaser may reasonably require or request in order to
effect the valid tender of such Stockholder’s Subject Shares in accordance with the terms of the Offer, and (b) instruct such Stockholder’s broker or such other Person that is the holder of record of any Shares beneficially owned
by the Stockholder to tender such Shares free and clear of all Encumbrances (other than Permitted Encumbrances) in accordance with this Section 1.1 and the terms of the Offer. Each Stockholder agrees that, once any of
such Stockholder’s Subject Shares are tendered, such Stockholder will not withdraw and will cause not to be withdrawn such Subject Shares from the Offer at any time, unless and until this Agreement shall have been validly terminated in
accordance with Section 6.2. Each Stockholder acknowledges and agrees that Purchaser’s obligation to accept for payment Shares tendered into the Offer, including any Subject Shares tendered by the Stockholder, is
subject to the terms and conditions of the Merger Agreement. 
 1.2    Agreement to Vote. Subject to the terms of
this Agreement, each Stockholder, severally and not jointly as to such Stockholder’s Subject Shares, hereby irrevocably and unconditionally agrees that, until the termination of this Agreement pursuant to Section 6.2,
at any annual or special meeting of the stockholders of the Company, however called, including any adjournment or postponement thereof, and in connection with any action proposed to be taken by written consent of the stockholders of the Company,
such Stockholder shall, in each case to the fullest extent that such Stockholder’s Subject Shares are entitled to vote thereon: (a) appear at each such meeting or otherwise cause all such Subject Shares to be counted as present thereat for
purposes of determining a quorum; and (b) be present (in person or by proxy) and vote (or cause to be voted), or deliver (or cause to be delivered) a written consent with respect to, all of its Subject Shares against (i) any Acquisition
Proposal and against any other action, agreement or transaction involving the Company that would reasonably be expected to cause the Company to abandon, terminate or fail to consummate the Offer or the Merger or (ii) any liquidation,
dissolution, extraordinary dividend or other significant corporate reorganization of 

  
 2 

 
the Company. Each Stockholder shall retain at all times the right to vote the Subject Shares in such Stockholder’s sole discretion, and without any other limitation, on any matters other
than those set forth in this Section 1.2 that are at any time or from time to time presented for consideration to the Company’s stockholders generally. 

ARTICLE II 

REPRESENTATIONS AND WARRANTIES OF THE STOCKHOLDERS 

Each Stockholder represents and warrants, severally and not jointly and on its own account with respect to the Subject Securities, to Parent
and Purchaser as to such Stockholder that: 
 2.1    Authorization; Binding Agreement. If such Stockholder is not
an individual, such Stockholder is duly organized and validly existing in good standing under the laws of the jurisdiction in which it is incorporated or constituted and the consummation of the transactions contemplated hereby are within such
Stockholder’s entity powers and have been duly authorized by all necessary entity actions on the part of such Stockholder, and such Stockholder has full power and authority to execute, deliver and perform this Agreement and to consummate the
transactions contemplated hereby. If such Stockholder is an individual, such Stockholder has full legal capacity, right and authority to execute and deliver this Agreement and to perform such Stockholder’s obligations hereunder. This Agreement
has been duly and validly executed and delivered by such Stockholder and constitutes a valid and binding obligation of such Stockholder enforceable against such Stockholder in accordance with its terms, subject to the effects of bankruptcy,
insolvency, fraudulent conveyance, reorganization, moratorium and other similar Legal Requirements relating to or affecting creditors’ rights generally and general equitable principles (whether considered in a proceeding in equity or at law).

 2.2    Non-Contravention. Neither the execution and delivery of this
Agreement by such Stockholder nor the consummation by such Stockholder of the transactions contemplated hereby nor compliance by such Stockholder with any provisions herein will (a) if such Stockholder is not an individual, contravene, conflict
with or result in a violation of any of the provisions of the certificate of incorporation, bylaws or other similar charter or organizational documents of such Stockholder, (b) require any consent, approval, authorization or permit of, or
filing with or notification to, any supranational, national, foreign, federal, state or local government or subdivision thereof, or governmental, judicial, legislative, executive, administrative or regulatory authority on the part of such
Stockholder, except for compliance with the applicable requirements of the Securities Act, the Exchange Act or any other United States or federal securities laws and the rules and regulations promulgated thereunder, (c) contravene, conflict
with or result in a violation or breach of, or result in a default under (or give rise to any right of termination, cancellation, modification or acceleration) under any of the terms, conditions or provisions of any note, license, agreement,
contract, indenture or other instrument or obligation to which such Stockholder is a party or by which such Stockholder or any of its assets may be bound, (d) result (or, with the giving of notice, the passage of time or otherwise, would
result) in the creation or imposition of any mortgage, lien, pledge, charge, security interest or encumbrance of any kind on any asset of such Stockholder (other than one created by Parent or Purchaser), or (e) violate any order, writ,
injunction, decree, statute, rule or regulation applicable to such Stockholder or by which any of its assets are bound, except as 

  
 3 

 
would not, in the case of each of clauses (b), (c), (d) and (e), reasonably be expected to have, individually or in the aggregate, a material adverse effect on such Stockholder’s ability to
perform its obligations under this Agreement. 
 2.3    Ownership of Subject Shares; Total Shares. Such
Stockholder is the record and beneficial owner (as defined in Rule 13d-3 under the Exchange Act) of all such Stockholder’s Subject Securities and has good and marketable title to all such Subject
Securities free and clear of any liens, claims, proxies, voting trusts or agreements, options, rights, understandings or arrangements or any other encumbrances or restrictions whatsoever on title, transfer or exercise of any rights of such
Stockholder in respect of such Subject Securities (collectively, “Encumbrances”), except for any such Encumbrance that may be imposed pursuant to (i) this Agreement; (ii) any applicable restrictions on transfer under the
Securities Act or any other applicable securities law, (iii) any written policies of the Company with respect to the trading of securities in connection with insider trading restrictions, applicable securities laws and similar considerations;
(iv) any lien for current Taxes not yet due and payable or Taxes being contested in good faith by appropriate proceedings; and (v) liens that do not (in any individual case or in the aggregate) restrict in any material respect the ability
of such Stockholder to comply with its obligations under this Agreement (collectively, “Permitted Encumbrances”). Except to the extent acquired after the date hereof, the Subject Shares listed on Schedule A opposite such
Stockholder’s name constitute all of the shares of “voting stock” of the Company of which such Stockholder is the “owner” (as such terms are defined in Section 203 of the Delaware General Corporation Law) as of the time
that the Company Board approved the Merger Agreement. 
 2.4    Voting Power. Such Stockholder has full voting
power with respect to all such Stockholder’s Subject Shares, and full power of disposition (except for Permitted Encumbrances), full power to issue instructions with respect to the matters set forth herein and full power to agree to all of the
matters set forth in this Agreement, in each case with respect to all such Stockholder’s Subject Securities. None of such Stockholder’s Subject Shares are subject to any stockholders’ agreement, proxy, voting trust or other agreement
or arrangement with respect to the voting of such Subject Shares, except as provided hereunder. 

2.5    Reliance. Such Stockholder understands and acknowledges that Parent and Purchaser are entering into the
Merger Agreement in reliance upon such Stockholder’s execution, delivery and performance of this Agreement. 

2.6    Absence of Litigation. With respect to such Stockholder, as of the date hereof, there is no Legal Proceeding
pending against, or, to the actual knowledge of such Stockholder, threatened in writing against such Stockholder or any of such Stockholder’s properties or assets (including any Shares beneficially owned by such Stockholder) before or by any
Governmental Body that would reasonably be expected to prevent or otherwise materially impair the ability of such Stockholder to perform the obligations of such Stockholder under this Agreement. 

ARTICLE III 

REPRESENTATIONS AND WARRANTIES OF PARENT AND PURCHASER 

Parent and Purchaser represent and warrant to the Stockholders that: 

  
 4 

 3.1    Organization and Qualification. Each of Parent and
Purchaser is a duly organized and validly existing corporation in good standing under the laws of the jurisdiction of its organization. 

3.2    Authority for this Agreement. Each of Parent and Purchaser has all requisite entity power and authority to
execute, deliver and perform its obligations under this Agreement and to consummate the transactions contemplated hereby. The execution and delivery of this Agreement by Parent and Purchaser have been duly and validly authorized by all necessary
entity action on the part of each of Parent and Purchaser, and no other entity proceedings on the part of Parent and Purchaser are necessary to authorize this Agreement. This Agreement has been duly and validly executed and delivered by Parent and
Purchaser and, assuming the due authorization, execution and delivery by the Stockholder, constitutes legal, valid and binding obligation of each of Parent and Purchaser, enforceable against each of Parent and Purchaser in accordance with its terms,
subject to the effects of bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other similar Legal Requirements relating to or affecting creditors’ rights generally and general equitable principles (whether considered
in a proceeding in equity or at law). 
 ARTICLE IV 

ADDITIONAL COVENANTS OF THE STOCKHOLDERS 

Each Stockholder, severally and not jointly and solely with respect to such Stockholder’s Subject Shares, hereby covenants and agrees
that until the termination of this Agreement: 
 4.1    No Transfer or Encumbrance; No Inconsistent Arrangements.
Except as provided hereunder or under the Merger Agreement, from and after the date hereof and until this Agreement is terminated, such Stockholder shall not, directly or indirectly, (a) create or permit to exist any Encumbrance, other than
Permitted Encumbrances, on any of such Stockholder’s Subject Shares, (b) transfer, sell, assign, gift, hedge, pledge or otherwise dispose of, or enter into any derivative arrangement with respect to (collectively,
“Transfer”), any of such Stockholder’s Subject Shares, or any right or interest therein (or consent to any of the foregoing), (c) enter into any Contract providing for any Transfer of such Stockholder’s Subject Shares or
any interest therein, (d) grant or permit the grant of any proxy, power-of-attorney or other authorization or consent in or with respect to any such
Stockholder’s Subject Shares, (e) deposit or permit the deposit of any of such Stockholder’s Subject Shares into a voting trust or enter into a voting agreement or arrangement with respect to any of such Stockholder’s Subject
Shares, (f) between the Acceptance Time and the Effective Time, exercise all or any portion of any Subject Warrant or (g) take or permit any other action that would restrict, limit or interfere with the performance of such
Stockholder’s obligations hereunder in any material respect. Any action taken in violation of the foregoing sentence shall be null and void ab initio. Notwithstanding the foregoing, any Stockholder may Transfer Subject Shares (i) to
any member of such Stockholder’s immediate family, (ii) to a trust for the sole benefit of such Stockholder or any member of such Stockholder’s immediate family, the sole trustees of which are such Stockholder or any member of such
Stockholder’s immediate family or (iii) by will or under the laws of intestacy upon the death of such Stockholder, provided, that a transfer referred to in clause (i) through (iii) of this sentence shall be permitted only if
all the representations and warranties in this Agreement with respect to such Stockholder would, to the extent applicable, be true and 

  
 5 

 
correct upon such Transfer and the transferee agrees in writing to accept such Subject Shares subject to the terms of this Agreement and to be bound by the terms of this Agreement and to agree
and acknowledge that such Person shall constitute a “Stockholder” for all purposes of this Agreement. If any involuntary Transfer of any of such Stockholder’s Subject Shares in the Company shall occur (including, but not limited to, a
sale by such Stockholder’s trustee in any bankruptcy, or a sale to a purchaser at any creditor’s or court sale), the transferee (which term, as used herein, shall include any and all transferees and subsequent transferees of the initial
transferee) shall take and hold such Subject Shares subject to all of the restrictions, liabilities and rights under this Agreement, which shall continue in full force and effect until valid termination of this Agreement. Notwithstanding the
foregoing, such Stockholder may make Transfers of its Subject Shares as Parent may agree in writing in its sole discretion. 

4.2    Documentation and Information. From the date of this Agreement until the Closing, such Stockholder shall not
make any public announcement regarding this Agreement, the Contemplated Transactions and the other transactions contemplated hereby without the prior written consent of Parent, except (a) as may be required by applicable Legal Requirements
(provided that reasonable notice of any such disclosure will be provided to Parent) or (b) to the extent such announcement contains information that has been previously disclosed publicly. Such Stockholder consents to and hereby authorizes
Parent and Purchaser to publish and disclose in all documents and schedules filed with the SEC, and any press release or other disclosure document necessary in connection with the Offer, the Merger and the other Contemplated Transactions, the
existence of this Agreement and the nature of such Stockholder’s commitments and obligations under this Agreement, and such Stockholder acknowledges that Parent and Purchaser may, in Parent’s sole discretion, file this Agreement or a form
hereof with the SEC or any other Governmental Body. Such Stockholder agrees to promptly give Parent and the Company any information either may reasonably require for the preparation of any such disclosure documents, and such Stockholder agrees to
promptly notify Parent and the Company upon becoming aware of any required corrections with respect to any written information supplied by such Stockholder specifically for use in any such disclosure document, if and to the extent that any such
information shall have become false or misleading in any material respect. 
 4.3    Adjustments. In the event of
any stock split, stock dividend, merger, reorganization, recapitalization, reclassification, combination, exchange of shares or the like of the capital stock of the Company affecting the Subject Shares, the terms of this Agreement shall apply to the
resulting securities. 
 4.4    Waiver of Certain Actions. Each Stockholder hereby agrees not to commence or
participate in, and to take all actions necessary to opt out of any class in any class action with respect to, any claim, derivative or otherwise, against Parent, Purchaser or any of their respective successors (a) challenging the validity of,
or seeking to enjoin or delay the operation of, any provision of this Agreement or the Merger Agreement (including any claim seeking to enjoin or delay the Offer or the Closing) or (b) alleging a breach of any duty of the Company Board in
connection with the Merger Agreement, this Agreement or the transactions contemplated thereby or hereby. 
 4.5    No
Solicitation. Subject to Section 4.4 (No Solicitation) of the Merger Agreement, each Stockholder agrees that such Stockholder shall immediately cease any 

  
 6 

 
solicitation, discussions or negotiations with any Persons that may be ongoing by such Stockholder as of the date of this Agreement with respect to an Acquisition Proposal. Until the Specified
Time, such Stockholder shall not, directly or indirectly, (a) solicit, initiate or knowingly facilitate or knowingly encourage any inquiries or the making of any proposal or offer that constitutes, or would reasonably be expected to lead to, an
Acquisition Proposal or (b) engage in, continue or otherwise participate in any discussions or negotiations regarding, or furnish to any other Person any non-public information in connection with an
Acquisition Proposal or any proposal or offer that would reasonably be expected to lead to an Acquisition Proposal. 
 ARTICLE V 

WARRANT TREATMENT 
 (a)
Each Stockholder acknowledges and agrees, severally and not jointly and solely with respect to such Stockholder’s Subject Warrants, that, at the Effective Time, each Subject Warrant owned by such Stockholder that is then-outstanding and
unexercised as of immediately prior to the Effective Time shall, pursuant to the terms hereof and as a result of the Merger and without any other action on the part of such Stockholder, receive, in lieu of any other amount or consideration to which
such Stockholder might otherwise have been entitled to receive pursuant to such Subject Warrant, (i) $[2.47] in cash for each share of Company Common Stock for which such November Warrant (as set forth on Schedule A) was exercisable immediately
prior to the Effective Time (subject to adjustment in the event of a stock split, division or subdivision, stock dividend, reverse stock split, consolidation, reclassification, recapitalization or other similar transaction affecting the Company
Common Stock), plus (ii) $[2.47] in cash for each share of Company Common Stock for which such January Warrant (as set forth on Schedule A) was exercisable immediately prior to the Effective Time (subject to adjustment in the event of a stock split,
division or subdivision, stock dividend, reverse stock split, consolidation, reclassification, recapitalization or other similar transaction affecting the Company Common Stock), in each case subject to Section 1.12 of the Merger Agreement. 

(b) At the Effective Time, each Pre-Funded Warrant that is then-outstanding and unexercised as of
immediately prior to the Effective Time shall, as a result of the Merger and without any action on the part of any holder of a Pre-Funded Warrant, receive, in lieu of any other amount or consideration to which
such Stockholder might otherwise have been entitled to receive pursuant to such Pre-Funded Warrant, the product of (i) (A) the aggregate number of shares of Company Common Stock for which such Pre-Funded Warrant was exercisable immediately prior to the Effective Time, multiplied by (B) in the case of November Pre-Funded Warrants (set forth on Schedule B),
[99.441341%], and in the case of January Pre-Funded Warrants (set forth on Schedule B), [99.944134%], and (ii) the Offer Price. 

ARTICLE VI 

MISCELLANEOUS 

6.1    Notices. All notices, requests, demands and other communications under this Agreement shall be in writing
and shall be deemed to have been duly given or made as follows: (a) if sent by registered or certified mail in the United States return receipt requested, upon receipt; (b) if sent designated for overnight delivery by nationally recognized
overnight air 

  
 7 

 
courier (such as Federal Express), one business day after mailing; (c) if sent by facsimile transmission or e-mail before 5:00 p.m. Eastern Time, when
transmitted and receipt is confirmed; (d) if sent by facsimile transmission or e-mail after 5:00 p.m. Eastern Time and receipt is confirmed, on the following business day; and (e) if otherwise
actually personally delivered, when delivered; provided, that the notice or other communication is sent to the address, facsimile number or email address set forth (i) in the case to Parent or Purchaser, to the address or e-mail address set forth in Section 9.9 of the Merger Agreement and (ii) if to a Stockholder, to such Stockholder’s address, facsimile number or e-mail address
set forth on a signature page hereto, or to such other address, facsimile number or e-mail address as such party may hereafter specify for the purpose by notice to each other party hereto. 

6.2    Termination. This Agreement shall terminate automatically with respect to a Stockholder, without any notice
or other action by any Person, upon the first to occur of (a) the termination of the Merger Agreement in accordance with its terms, (b) the Effective Time, (c) any amendment to the Merger Agreement that reduces the amount, or changes
the form, of consideration payable to such Stockholder in the Contemplated Transactions, imposes additional restrictions on such Stockholder or otherwise materially and adversely impacts such Stockholder, (d) a Company Adverse Change in
Recommendation or (e) the mutual written consent of Parent and such Stockholder. Upon termination of this Agreement, no party shall have any further obligations or liabilities under this Agreement; provided, however, that
(x) nothing set forth in this Section 6.2 shall relieve any party from liability for any Willful Breach of this Agreement prior to termination hereof and (y) the provisions of this Article VI shall survive
any termination of this Agreement. 
 6.3    Amendments and Waivers. 

(a)    Any provision of this Agreement may be amended or waived if such amendment or waiver is in writing and is signed,
in the case of an amendment, by each party to this Agreement or, in the case of a waiver, by each party against whom the waiver is to be effective. 

(b)    No failure on the part of any party to exercise any power, right, privilege or remedy under this Agreement, and no
delay on the part of any party in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege or remedy; and no single or partial exercise of any such power, right, privilege or
remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy. 

6.4    Expenses. All fees and expenses incurred in connection herewith and the transactions contemplated hereby
shall be paid by the party incurring such fees and expenses, whether or not the Offer and the Merger are consummated. 

6.5    Entire Agreement; Assignment. This Agreement, together with Schedule A, and the other documents and
certificates delivered pursuant hereto, constitute the entire agreement, and supersede all prior agreements and understandings, both written and oral, among the parties with respect to the subject matter of this Agreement. Neither this Agreement nor
any party’s rights or obligations hereunder may be assigned or delegated by such party without the prior 

  
 8 

 
written consent of the other parties, and any attempted assignment or delegation of this Agreement or any of such rights or obligations by any party without the prior written consent of the other
parties shall be void and of no effect; provided, that Parent or Purchaser may assign any of their respective rights and obligations to any direct or indirect Subsidiary of Parent, but no such assignment shall relieve Parent or Purchaser, as
the case may be, of its obligations hereunder. 
 6.6    Enforcement of the Agreement. The parties agree that
irreparable damage would occur in the event that any Stockholder did not perform any of the provisions of this Agreement in accordance with their specific terms or otherwise breached any such provisions. It is accordingly agreed that Parent and
Purchaser shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement in addition to any other remedy to which they are entitled at law or in equity.
Any and all remedies herein expressly conferred upon Parent and Purchaser will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon Parent or Purchaser, and the exercise by Parent or Purchaser of
any one remedy will not preclude the exercise of any other remedy. 
 6.7    Jurisdiction; Waiver of Jury Trial.

 (a)    This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware,
without giving effect to any laws, rules or provisions that would cause the application of the laws of any jurisdiction other than the State of Delaware. In any action between any of the parties arising out of or relating to this Agreement or the
transactions contemplated hereby, each of the parties irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Chancery Court of the State of Delaware. The parties agree that irreparable damage would occur
and that the parties would not have any adequate remedy at law in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the parties
shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement, this being in addition to any other remedy to which they are entitled at law or in
equity. All rights and remedies existing under this Agreement are cumulative to, and not exclusive of, any rights or remedies otherwise available. Each Stockholder hereby agrees that service of any process, summons, notice or document by U.S.
registered mail in accordance with Section 6.1 shall be effective service of process for any proceeding arising out of, relating to or in connection with this Agreement or the transactions contemplated hereby. 

(b)    EACH STOCKHOLDER ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO
INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN ANY LITIGATION ARISING OUT OF, RELATING TO OR IN CONNECTION WITH THIS
AGREEMENT. EACH STOCKHOLDER CERTIFIES AND ACKNOWLEDGES THAT (I) NO REPRESENTATIVE, AGENT OR ATTORNEY OF PARENT OR PURCHASER HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT PARENT OR PURCHASER WOULD NOT, IN THE

  
 9 

 
EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (II) EACH STOCKHOLDER UNDERSTANDS AND HAS CONSIDERED THE IMPLICATION OF THIS WAIVER, (III) EACH STOCKHOLDER MAKES THIS WAIVER
VOLUNTARILY, AND (IV) EACH STOCKHOLDER HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION. 

6.8    Descriptive Headings. The descriptive headings herein are inserted for convenience of reference only and are
not intended to be part of or to affect the meaning or interpretation of this Agreement. 
 6.9    Parties in
Interest. This Agreement shall be binding upon and inure solely to the benefit of each party hereto, and nothing in this Agreement, express or implied, is intended to confer upon any other Person any rights or remedies of any nature whatsoever
under or by reason of this Agreement. 
 6.10    Severability. Any term or provision of this Agreement that is
invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other
situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision of this Agreement is invalid or unenforceable, the parties hereto agree that the court making such determination
shall have the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid
or unenforceable term or provision, and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the parties hereto agree to replace such invalid or
unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision. 

6.11    Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed to be an
original, but all of which, taken together, shall constitute one and the same agreement. This Agreement or any counterpart may be executed and delivered by facsimile copies or delivered by electronic communications by portable document format
(.pdf), each of which shall be deemed an original. 
 6.12    Construction. 

(a)    For purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and
vice versa; the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine genders. 

(b)    The parties hereto agree that any rule of construction to the effect that ambiguities are to be resolved against
the drafting party shall not be applied in the construction or interpretation of this Agreement. 

  
 10 

 (c)    As used in this Agreement, the words “include” and
“including,” and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words “without limitation.” 

(d)    Except as otherwise indicated, all references in this Agreement to “Sections” and
“Schedules” are intended to refer to Sections of this Agreement and Schedules to this Agreement. 

(e)    The bold-faced headings contained in this Agreement are for convenience of reference only, shall not be deemed to
be a part of this Agreement and shall not be referred to in connection with the construction or interpretation of this Agreement. 

6.13    Further Assurances. Each Stockholder will execute and deliver, or cause to be executed and delivered, all
further documents and instruments and use its reasonable best efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary, proper or advisable under applicable Legal Requirements, to perform its
obligations under this Agreement. 
 6.14    No Agreement Until Executed. This Agreement shall not be effective
unless and until (a) the Merger Agreement is executed by all parties thereto and (b) this Agreement is executed by all parties hereto. 

6.15    Stockholder Obligation Several and Not Joint. The obligations of each Stockholder hereunder shall be
several and not joint, and no Stockholder shall be liable for any breach of the terms of this Agreement by any other Stockholder. 

6.16    Capacity as Stockholder. Each Stockholder signs this Agreement solely in such Stockholder’s capacity
as a stockholder and warrantholder of the Company, and not in such Stockholder’s capacity as a director, officer or employee of the Company. Notwithstanding anything herein to the contrary, nothing herein shall in any way restrict a director or
officer of the Company (including any director or officer who is an Affiliate of a Stockholder) in the taking of any actions (or failure to act) in his or her capacity as a director or officer of the Company, or in the exercise of his or her
fiduciary duties as a director or officer of the Company, or prevent or be construed to create any obligation on the part of any director or officer of the Company from taking any action in his or her capacity as such director or officer, and no
action taken in any such capacity as an officer or director of the Company shall be deemed to constitute a breach of this Agreement. 

[Signature Pages Follow] 

  
 11 

 The parties are executing this Agreement on the date set forth in the introductory clause.

  

			
	PARENT
	
	MELINTA THERAPEUTICS, INC.

 
			
		
	By:	 	  

	Name:	 	
	Title:	 	

 
			
	
	PURCHASER
	
	TORONTO TRANSACTION CORP.

 
			
		
	By:	 	  

	Name:	 	
	Title:	 	

 [Signature Page to Tender and Support Agreement] 

 
			
	STOCKHOLDER
	
	[STOCKHOLDER]

 
			
		
	By:	 	  

		 	Name:
		 	Title:
	
	Address: [●]

 [Signature Page to Tender and Support Agreement] 

 Schedule A 

 

											
	 Stockholder
	 	 Subject
Shares
	 	 November
Warrants
	  	 January
Warrants
	  	 Date
of
Issuance of
Subject
Warrants
	  	 Number
of
Shares
Underlying
Subject
Warrants

		 		 		  		  		  	

 Schedule B 

 

									
	 Stockholder
	 	 November
Pre-Funded
Warrants
	 	 January
Pre-Funded
Warrants
	  	 Date of
Issuance of
Pre-Funded Warrants
	  	 Number of Shares
Underlying
Pre-Funded Warrants

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}]]